CM-24 + nivolumab + nab-paclitaxel + gemcitabine

CM-24 + nivolumab + nab-paclitaxel + gemcitabine is a combination therapy under investigation for the treatment of advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) and potentially other cancers. The regimen includes: - **CM-24**: A humanized monoclonal antibody that targets and blocks Carcinoembryonic Antigen Cell Adhesion Molecule 1 (CEACAM1), an immune checkpoint protein involved in tumor immune evasion, metastasis, and cancer progression. By inhibiting CEACAM1, CM-24 aims to reduce immunosuppression in the tumor microenvironment[1][4][5][8]. - **Nivolumab**: An anti-PD‑1 monoclonal antibody (brand name Opdivo) that blocks the programmed death 1 (PD‑1) receptor on T cells, enhancing anti-tumor immune responses[6]. - **Nab-paclitaxel**: An albumin-bound formulation of paclitaxel (brand name Abraxane), a chemotherapy agent that disrupts microtubule function in rapidly dividing cells. - **Gemcitabine**: A nucleoside analog chemotherapy drug (brand name Gemzar) that inhibits DNA synthesis in cancer cells[7]. This combination is being evaluated in Phase 2 clinical trials for patients with PDAC who have progressed after first-line therapy. The rationale is to combine immunotherapy agents targeting different checkpoints with standard-of-care chemotherapy to improve outcomes over chemotherapy alone[4][5][8].

Brand names

OpdivoGemzarAbraxane

Other names

CM24 + nivolumab + gemcitabine + nab-paclitaxel